As of 2026, 11% of American adults now take a GLP-1 medication, nearly four times the rate reported in 2024. As doctors continue to prescribe these drugs, researchers continue to search for new and improved formulations. 

Retatrutide, a weekly injection currently in clinical trials, stands out. Its Phase 3 data shows weight loss numbers that exceed those of tirzepatide, making it potentially more powerful than any FDA-approved option available today. However, its long-term safety and real-world effects remain unproven.

This article breaks down retatrutide versus tirzepatide, including how they work, what the clinical trials show, and how safe they are. This will help you understand what the latest developments mean for your weight loss journey.

‍

What’s the difference between retatrutide and tirzepatide?

Traditional weight loss medications like Wegovy® (semaglutide) and Saxenda® (liraglutide) are mono hormone receptor agonists. This means that they mimic one hormone your gut naturally produces after a meal: glucagon-like peptide-1 (GLP-1). GLP-1 works in your body in several ways:

• Insulin secretion: After a meal, your blood sugar (glucose) levels rise. When this happens, GLP-1 directs your pancreas to make and release insulin in order to move glucose out of your bloodstream and into your cells to be used for fuel.
• Glucagon suppression: At the same time, GLP-1 limits glucagon, the hormone that tells your liver to release stored glucose. This prevents your liver from dumping extra sugar into your bloodstream between meals, which helps you maintain stable blood sugar.
• Gastric emptying: GLP-1 also tells the muscles in your stomach to relax so food digests at a slower rate. This means the sugar from your meal enters your bloodstream more gradually, preventing a post-meal blood sugar spike and keeping you fuller for longer.
• Satiety: The hormone also travels to the appetite center of your brain (hypothalamus) to quiet hunger signals and prolong fullness sensations. This helps you feel more satisfied with less food.

Tirzepatide: A dual receptor agonist

On top of GLP-1, tirzepatide also mimics a second hormone, glucose-dependent insulinotropic polypeptide (GIP). GIP also tells your pancreas to make insulin when your blood sugar rises, increasing the effects of GLP-1. In addition, this hormone improves the storage capacity of your fat (adipose) tissue. By helping under-the-skin (subcutaneous) fat expand safely to handle incoming nutrients, GIP prevents excess fat from spilling over and clustering around your organs as harmful visceral fat.

Retatrutide: A triple receptor agonist

Retatrutide further expands on GLP-1 and GIP, mimicking glucagon as well. Your pancreas releases glucagon between meals to pull stored glucose from your liver for quick energy. But retatrutide uses a milder, controlled version of glucagon that signals several messengers in your body. These messengers then clear away a molecule (malonyl-CoA) that prevents fat from entering your cells’ power source (mitochondria). Once this molecule clears, an enzyme on the outside of your mitochondria (CPT1) opens up and shuttles fatty acids inside to be burned as fuel. By adding this third hormone, retatrutide encourages your body to burn more calories at rest.

Here’s a side-by-side comparison:

‍

What the evidence shows on weight loss

Tirzepatide produces the highest weight loss of any FDA-approved obesity medication to date. Retatrutide's early results suggest this next-generation GLP-1 drug could go even further. However, comparing the two requires looking closely at study design, trial maturity, and important caveats regarding evidence quality. 

Tirzepatide’s results

The clinical evidence for tirzepatide’s efficacy is established and robust:

• SURMOUNT-1 trial participants lost an average of 22.5% of their body weight on the highest dose (15 mg) over 72 weeks. 
• Three-year follow up participants (who stayed on 15 mg) maintained a 19.7% mean change in body weight, down slightly from the 72-week peak, but stable over time. 
• SURMOUNT-5 trial participants on tirzepatide lost an average of 20.2% of their body weight versus 13.7% with semaglutide.

Retatrutide’s results

Retatrutide’s evidence is promising, but ongoing Phase 3 trials haven’t been peer-reviewed:

• TRIUMPH-1 trial participants lost an average of 28.3% of their body weight at 80 weeks while taking a 12 mg dose. 
• TRIUMPH-4 trial participants lost an average of 28.7% of their body weight at 68 weeks while taking a 12 mg dose.
• Continued treatment up to 104 weeks among participants with a starting BMI of 35 or higher lost an average of 30.3% of their body weight, a number until now only achieved with bariatric surgery.

Caveats to comparison

At the highest doses, retatrutide’s results outdo tirzepatide’s by roughly six percentage points. But no head-to-head trial between the two drugs exists. Additionally, the above numbers come from separate studies with different populations and durations. For example, TRIUMPH-1 participants started at a higher average BMI (40.0) than SURMOUNT-1 participants (38.0). Because people starting at higher weights may lose a larger overall percentage of body weight, trial populations play a significant role in the final percentages.

‍

Common side effects

Because both retatrutide and tirzepatide activate GLP-1 and GIP receptors, they share a similar set of gastrointestinal (GI) side-effects, including nausea, diarrhea, and vomiting. Most people experience these side effects during the early weeks of treatment or dose escalation as their bodies adjust to the medication.

However, the glucagon component of retatrutide introduces a unique side effect to about one in eight participants on higher doses. Dysesthesia causes unusual skin sensations like tingling or numbness. Most of these cases were mild and resolved during treatment.

‍

Safety concerns

Tirzepatide has been on the market since 2022, which means providers have a few years of real-world safety data to draw from. Rare but serious clinical risks include pancreatitis, gallbladder disease, and kidney injury. Tirzepatide also carries a black box warning for an increased risk of thyroid C-cell tumors and shouldn’t be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Because the medication is still going through clinical development, there’s no long-term safety data for retatrutide beyond two-year trial windows. Optimal dosing for different patient profiles, drug interactions, and effects in people with kidney or liver disease haven’t been established. When weighing Mounjaro® or Zepbound® versus retatrutide, it’s important to understand that these important safety questions won’t have clear answers until the FDA review process and real-world prescribing begin.

‍

Where retatrutide stands on FDA approval

The FDA hasn’t approved retatrutide for any use as of 2026. Eli Lilly plans to submit its application in early 2027. A standard review takes six to 10 months from submission, which means a decision could come in late 2027 or 2028.

But the agency granted the drug Fast Track designation in early 2024. This status allows more frequent communication between Eli Lilly and the FDA, and it could shorten the review timeline. The final doses and escalation schedule, insurance coverage, and retail pricing for retatrutide will likely all come out of the FDA review process. 

Beware of companies selling retatrutide illegally

Despite the fact that retatrutide hasn’t gone through FDA approval and isn’t available yet, some companies are already selling a form of medication that may not actually contain the correct active ingredient illegally. The FDA has issued warning letters to telehealth companies marketing it and suppliers selling it to compounding pharmacies. Any retatrutide obtained outside a clinical trial has no quality control, no dosing standardization, and no safety monitoring. For any decision about GLP-1 therapy, a provider you trust is the safest starting point.

‍

How Maven Clinic can help you understand the differences and make an informed choice

While retatrutide isn’t currently available, its Phase 3 trial results demonstrate a promising step forward in GLP-1 therapy. However, the FDA-approved options that exist today, like tirzepatide, semaglutide, and orforglipron, are already producing life-changing results.

Maven Clinic’s GLP-1 Care Program connects you with providers who can help you understand your options, weigh the evidence, and build a plan around that makes sense for you right now. And once retatrutide receives FDA approval and enters the market, your care team will be right there with you to evaluate the new data and determine if it’s the right next step for your goals.

Find out more about our approach to GLP-1 Care.